← All indications
Aspergillosis
Infections with fungi of the genus ASPERGILLUS.
Subtype terms (2)
More specific conditions that are subtypes of Aspergillosis in the MeSH hierarchy.
- Neuroaspergillosis
2 drugs approved
- Pulmonary Aspergillosis
1 drug experimental
Drugs by status
Approved for this indication (6)
Phase 4 trials (3)
Phase 3 trials (6)
Phase 2 trials (3)
Phase 1 trials (4)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (20)
- Gilead Sciences
- Merck
- Novartis
- Baylor University
- First People's Hospital of Hangzhou
- Guangzhou Medical University
- Katholieke Universiteit Leuven
- Melbourne Health
- Postgraduate Institute of Medical Education and Research
- Radboud University
- Red Cross Hospital, Hangzhou, China
- University of Toronto
- Capital Medical University
- Zhejiang University
- Ningbo No. 5 Hospital
- Hangzhou Red Cross Hospital
- Hangzhou Hospital of Traditional Chinese Medicine
- Second People's Hospital of Hangzhou
- Xiaoshan People's Hospital
- Huzhou University
Organization Involved with Phase 3 Indications (20)
- NeXstar Pharmaceuticals
- Regeneron
- Basilea Pharmaceutica
- Sanofi
- Cipla
- Proaparts srl
- Scynexis, Inc.
- Sponsor GmbH
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Duke University
- Singapore General Hospital
- National University of Singapore
- European Organisation for Research and Treatment of Cancer
- Janssen Pharmaceutica NV
- Ospedale Maggiore San Giovanni Bosco
- University of Poitiers
- Erasmus University Rotterdam
- Hopital Universitaire Hautepierre
- Vicuron Pharmaceuticals
Organization Involved with Phase 2 Indications (23)
- F2G Ltd.
- Vical
- Pulmatrix Inc.
- Pulmocide Ltd
- PETHEMA Foundation
- Fundació Sant Joan de Déu
- The Christie NHS Foundation Trust
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pittsburgh
- Hoosier Cancer Research Network
- Northern Italy Leukemia Group
- University of Liverpool
- Fudan University
- University of Cologne
- University of Texas, Galveston
- University of Barcelona
- Universidad Autonoma de Barcelona
- University of Genoa
- Spedali Civili di Brescia
- University of Rennes
- Government of Spain
- Syneos Health
- Shijiazhuang Pharma Group (CSPC)
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (7)